Nearly a whole year after the release of the UofCal@SF study that I got apabetalone into (March 2020), the CEO in February 2021 said shareholders should expect a quick and easy 100-patient 30-day P2 trial that would start recruiting "immediately" in March 2021 but might bleed in April (2021) and to expect a read-out for the P2 potentially in June 2021.  He tells us to expect a Phase 3 US trial to start in Q3 2021 (IIRC) with a read out potentially by EOY 2021.

Today is August 3 2021 and we are now told to expect

- P2 readout in Q4 2021
- P3 start in first half of 2022
- P3 readout in second half of 2022

Based on the reliability of our CEO's past forward-looking statements I would suggest that we add an additional year to all of the above time horizons for a more realistic setting of our expectations.

I quite honestly don't know if we have a CEO or a saboteur.   

JMHO